



Published: May 31, 2023

Citation: Peters VJT and de Winter JP, 2023. The Complexities of Down Syndrome Healthcare: Medical Comorbidities, and Care Models, Medical Research Archives, [online] 11(5).

DOI: <https://doi.org/10.18103/mra.v11i5.3956>

Copyright: © 2023 European Society of Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. DOI:

<https://doi.org/10.18103/mra.v11i5.3956>

ISSN: 2375-1924

RESEARCH ARTICLE

The Complexities of Down Syndrome Healthcare: Medical Comorbidities, and Care Models

Peters Vincent J.T. ^{1,2} & **de Winter J. Peter** ^{3,4,5}

¹ Department of Management, Tilburg University, Tilburg, Netherlands

² Department of Tranzo, Tilburg University, Tilburg, Netherlands

³ Department of Paediatrics, Spaarne Gasthuis, Haarlem and Hoofddorp, The Netherlands

⁴ Department of Development and Regeneration, KU Leuven, Leuven, Belgium

⁵ Leuven Child and Youth Institute, KU Leuven, Leuven, Belgium

*Corresponding Email: v.j.t.peters@tilburguniversity.edu

Main Text

Down syndrome (DS), often caused by trisomy 21, is the most common form of intellectual disability among newborn infants worldwide¹. Differences in annual live births have been observed per continent: around 17,000 annual live births of children with DS have been estimated in Europe², around 5,100 annual live births of children with DS have been estimated in the US³, and around 300 annual live births of children with DS have been estimated in Australia and New Zealand⁴. The presence of prenatal screening and elective terminations has negatively influenced the live birth rates of children with DS.

The availability and accessibility of prenatal testing (like non-invasive prenatal testing) and genetic counselling certainly have a current and future impact on the number of live births with DS⁵. In addition, there is a risk of the routinization of prenatal screening, where parents are no longer facilitated to make informed decisions based on their own moral and practical considerations, but family members, relatives, and friends alike, implicitly or explicitly expect that parents will choose prenatal screening, diagnostic testing, and, perhaps the termination of pregnancy^{6,7}. Such potential societal pressure may increase the effect of the availability of prenatal screening on the live birth rate of children with DS. Other factors - such as religious beliefs, economics, the complexity of society, changing maternal ages, cultural beliefs, and social norms - likely play additional roles. The anticipated quality of life for a person with DS might also be an essential consideration in the decision-making for some expectant parents⁶.

About live birth rates, the life expectancy of persons with DS has significantly increased in the last decades due to improvements in medical care, such as improvements in cardiac surgery, prevention of childhood infections, and broader access to standard care. This results in an expanding cohort of persons with DS who need medical care addressing their unique profile⁸. Given these developments, we aimed to provide a brief overview of progress made in the last few years regarding medical comorbidities and care models in the field of DS healthcare.

Persons with DS are known to have an intellectual disability and a variety of malformations like congenital heart defects, small ears, small mouths, and other physical findings¹, along with medical conditions like hip dislocation⁹ and leukaemia¹⁰. Many medical conditions are more common in individuals with DS than the general population and affect health, development, and daily functioning. Therefore, secondary

screening for comorbidity is an essential part of the care of persons with DS¹¹. DS is associated with medical comorbidities and disorders that differ from population rates and impact organ systems throughout the body. As a result, persons with DS have an increased risk for conditions like obstructive sleep apnea¹², obesity¹, hearing problems¹³, vision problems¹⁴, congenital heart diseases¹⁵, autism¹⁶, regression disorder¹⁷, and Alzheimer's disease^{18,19}, among others^{1,20}. The healthcare professionals most frequently involved in treating these comorbidities are paediatricians, cardiologists, ophthalmologists, ENT physicians, dieticians, speech therapists, orthopaedic surgeons, physiotherapists, (paediatric) cardiologist, psychologist, and education generalist¹¹.

The best follow-up for persons with DS involves regular medical check-ups, developmental assessments, and social support. Medical check-ups should be scheduled every year or as recommended national guidelines to monitor any health concerns or conditions that may develop^{10,21}. Developmental assessments help identify learning difficulties and other developmental delays, allowing for early intervention and tailored support. Social support is essential, including education and training for family members and caregivers on how to provide persons with DS with a supportive environment where they can thrive. This deserves attention from the moment the information about a suspected DS diagnosis, either before or after birth, is communicated with family members and caregivers²². Additionally, access to therapy and programs that promote social interaction, life skills, and independent living can help promote a high quality of life for persons with DS.

With declining birth rates yet a higher prevalence of childhood and adult survivors with DS, it is important to identify the optimal model to deliver care for persons with DS in all life stages. Finding the optimal care model is especially relevant because although each separate clinical problem is often well known, the personal tailoring of the screening, prevention, and treatment in an individual with DS makes the organization and delivery of DS healthcare complex. Around the globe, there is significant variability in content, organization, provision, and access to care for persons with DS. They follow different models, serve different populations by age or location, and are organized by different medical specialties²³. This diversity hampers the implementation of personalized care and leads to unmet care needs all around the globe. For example, in the US, specialty DS clinics exist where some see only the paediatric population, whereas others provide care

restricted to adults²⁴. In Europe, multidisciplinary care for children with DS is organized in various forms: in the Netherlands, paediatric outpatient clinics organize multidisciplinary team appointments^{20,25}, and in Israel, multidisciplinary centers provide holistic care to persons with DS²⁶. In Asia, integrated care for children with DS is realized by organizing multidisciplinary care with protocol-driven surveillance in Taiwan²⁷, and clinical guideline management by physicians in Singapore²⁸. The importance of specialty clinics is also recognized in other countries like Oman²⁹.

Although various care models have been reported in the literature, there is no evidence that one model is more effective than others. Therefore, the variety in care models should make us pause and re-consider who should care for children with DS, and how that care should be delivered and organized. First steps are made in this regard by, for example, using a modular decomposition approach to provide insight into the underlying organizational structure of healthcare provision, which provides opportunities to offer persons with DS individualized healthcare based on their needs and requirements^{25,30,31}. These first steps could eventually influence the quality of healthcare for persons with DS³² and, consequently, the quality of life in persons with DS³³.

There are several areas of investigation that could be explored to understand the long-term outcomes of persons with DS. Some potential avenues of research might include 1) Medical follow-up: persons with DS are at increased risk for a variety of medical conditions, including heart defects, thyroid disease, and Alzheimer's disease. Studying long-term outcomes could involve tracking the incidence and progression of these conditions, as well as evaluating the effectiveness of different interventions or even medical treatments, 2) Intellectual development: long-term studies could explore the factors that contribute to intellectual development over time, as well as strategies for maximizing potential in different areas of functioning, and 3) Occupational and social outcomes: persons with DS often face employment discrimination and social isolation, despite the fact that many are capable of living independently and contributing to society.

Although DS is an incredibly complex, multi-system condition, the affected persons, their family members and caregivers, and involved healthcare professionals in both paediatric and adult care provision have an opportunity to collaborate and provide new insight into complex care delivery in the 21st century. One opportunity is actively involving persons with DS in health research, also

known as inclusive health research³⁴. However, historically persons with DS have been excluded from (clinical) research and family members and/or caregivers have served as a proxy³⁵. This has proven helpful given that family members and caregivers often have more experience and expertise about their offspring, since they are in the lead of care content and organization. Hence, they face the life-long challenge of negotiating health and social service systems for these persons with DS who depend on others to understand and explain their needs. Although family members and caregivers are often used as proxies in paediatric care, differences between children and their proxies have been reported. Therefore, it might be worth exploring whether persons with DS, in addition to caregivers, could also serve as experts-by-experience in inclusive health research to capture the full potential of these persons.

Another opportunity arises concerning the transition from paediatric to adult care. This transition has many challenges, crossing all dimensions of life. Persons with DS and caregivers need to find adult healthcare providers, ensure insurance coverage, and, where possible, take ownership of their health maintenance. In parallel, transition in various other spheres, such as educational, vocational, financial, social, guardianship, and legal responsibilities²³. Despite the attributed importance of this transition, only a few studies have been conducted on the transition of care for persons with DS³⁶, and no consensus has been reached on the organization of care transition for persons with DS.

Last, an increasing number of persons, besides persons with DS, live with complex care needs resulting from incredibly complex, multi-system conditions³⁷. Due to lifelong care needs on multiple life domains, these persons present a challenging task for healthcare professionals and care systems to provide optimal personalized care, taking both the characteristics of the genetic disorder and the individual into account. The progress in the field of DS can be extrapolated to offer directions for dealing with complex care needs for persons with other rare genetic disorders like 22q11 deletion syndrome³⁸, Williams syndrome³⁹, and Phelan-McDermid syndrome⁴⁰.

The manifestations of DS are complex, warranting (ideally) expert and multidisciplinary care in all life stages. Due to lifelong care needs, persons with DS present a challenging task for health care providers and care systems all over the world to provide optimal care, taking both the characteristics of the genetic disorder as well as the individual needs into account. In the present paper,

we present an overview of progress made in the last few years regarding medical comorbidities and care models in the field of DS healthcare. We hope this overview is inspiring and leads to avenues for future research.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

References

1. Bull MJ. Down syndrome. *The New England Journal of Medicine*. 2020;382(24):2344-2352. <https://doi.org/10.1056/NEJMra1706537>
2. de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in Europe. *European Journal of Human Genetics*. 2021;29:402-410. <https://doi.org/10.1038/s41431-020-00748-y>
3. de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in the United States. *Genetics in Medicine*. 2017;19(4):439-447. <https://doi.org/10.1038/gim.2016.127>
4. de Graaf G, Skladzien E, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in Australia and New Zealand. *Genetics in Medicine*. 2022;24(12):2568-2577. <https://doi.org/10.1016/j.gim.2022.08.029>
5. Wilmot HC, de Graaf G, van Casteren P, Buckley F, Skotko BG. Down syndrome screening and diagnosis practices in Europe, United States, Australia, and New Zealand from 1990-2021. *European Journal of Human Genetics*. 2023. <https://doi.org/10.1038/s41431-023-01330-y>
6. Crombag NM, Page-Christiaens GC, Skotko BG, de Graaf G. Receiving the news of Down syndrome in the era of prenatal testing. *American Journal of Medical Genetics: Part A*. 2020;182:374-385. <https://doi.org/10.1002/ajmg.a.61438>
7. de Groot-van der Mooren M, de Graaf G, Weijerman ME, Hoffer MJV, Knijnenburg J, et al. Does non-invasive prenatal testing affect the livebirth prevalence of Down syndrome in the Netherlands? A population-based register study. *Prenatal Diagnosis*. 2021;41(10):1351-1359. <https://doi.org/10.1002/pd.6003>
8. van den Driessen Mareeuw FA, Coppus AMW, Delnoij DMJ, de Vries E. Capturing the complexity of healthcare for people with Down syndrome in quality indicators - A Delphi study involving healthcare professionals and patient organisations. *BMC Health Services Research*. 2020;20(1):694. <https://doi.org/10.1186/s12913-020-05492-z>
9. Mulder FECM, Bok LA, van Douveren FQMP, Pruijs HEH, Zeegers AVCM. Effect of the Sharrard procedure on hip instability in children with Down syndrome: A retrospective study. *Journal of Children's Orthopaedics*. 2021;15(5):488-495. <https://doi.org/10.1302/1863-2548.15.210052>
10. Goemans, B.F., Noort, S., Blink, M, Wang, Y, Peters, STCJ, et al. Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia. *Leukemia*. 2021;35:2403-2406. <https://doi.org/10.1038/s41375-021-01128-1>
11. van Gameren-Oosterom HBM, Weijerman ME, van Wieringen H, de Winter JP, van Wermeskerken AM. Clinical practice - Latest insights in optimizing the care of children with Down syndrome. *European Journal of Pediatrics*. 2023. <https://doi.org/10.1007/s00431-023-04890-9>
12. Maris M, Verhulst S, Wojciechowski M, Van de Heyning P, Boudewyns A. Sleep problems and obstructive sleep apnea in children with Down syndrome, an overview. *International Journal of Pediatric Otorhinolaryngology*. 2016;82:12-15. <https://doi.org/10.1016/j.ijporl.2015.12.014>
13. Bull MJ. Improvement of outcomes for children with Down syndrome. *The Journal of Pediatrics*. 2018;193:9-10. <https://doi.org/10.1016/j.jpeds.2017.11.014>
14. de Weger C, Boonstra N, Goossens J. Effects of bifocals on visual acuity in children with DS: A randomized controlled trial. *Acta Ophthalmologica*. 2019;97(4):378-393. <https://doi.org/10.1111/aos.13944>
15. Martin T, Smith A, Breatnach CR, Kent E, Shanahan, I, et al. Infants born with Down syndrome: Burden of disease in the early neonatal period. *The Journal of Pediatrics*. 2018;193:21-26. <https://doi.org/10.1016/j.jpeds.2017.09.046>
16. Godfrey M, Hepburn S, Fidler DJ, Tapera T, Zhang F, et al. Autism spectrum disorder (ASD) symptom profiles of children with comorbid Down syndrome (DS) and ASD: A comparison with children with DS-only and ASD-only. *Research in Developmental Disabilities*. 2019;89:83-93. <https://doi.org/10.1016/j.ridd.2019.03.003>
17. Santoro JD, Filipink RA, Baumer NT, Bulova PD, Handen BL. Down syndrome regression disorder: Updates and therapeutic advances. *Current Opinion in Psychiatry*. 2023;36(2):96-103. <https://doi.org/10.1097/YCO.0000000000000845>

18. Rafii MS, Kleschevnikov AM, Sawa M, Mobley WC. Down syndrome. *Handbook of Clinical Neurology*. 2019;167:321-336. <https://doi.org/10.1016/B978-0-12-804766-8.00017-0>
19. Lorenzon N, Musoles-Lleó J, Turrisi F, Gomis-González M, De La Torre R, et al. State-of-the-art therapy for Down syndrome. *Developmental Medicine and Child Neurology*. 2023. <https://doi.org/10.1111/dmcn.15517>
20. Weijerman ME, de Winter JP. Clinical practice: The care of children with Down syndrome. *European Journal of Pediatrics*. 2010;169(12):1445-1452. <https://doi.org/10.1007/s00431-010-1253-0>
21. Bull MJ. Health supervision for children with Down syndrome. *Pediatrics*. 2011;128(2):393-406. <https://doi.org/10.1542/peds.2011-1605>
22. Gori C, Cocchi G, Corvaglia LT, Ramacieri G, Pulina F, et al. Down Syndrome: How to communicate the diagnosis. *Italian Journal of Pediatrics*. 2023;49(1):18. <https://doi.org/10.1186/s13052-023-01419-6>
23. Fisher PG. Who should care for children with Down syndrome. *The Journal of Pediatrics*. 2020;218:1-4. <https://doi.org/10.1016/j.jpeds.2020.01.024>
24. Joslyn N, Berger H, Skotko BG. Geospatial analyses of accessibility to Down syndrome specialty care. *The Journal of Pediatrics*. 2020;218:146-150. <https://doi.org/10.1016/j.jpeds.2019.10.058>
25. Fransen L, Peters VJT, Meijboom BR, de Vries E. Modular service provision for heterogeneous patient groups: A single case study in chronic Down syndrome care. *BMC Health Services Research*. 2019;19(1):720. <https://doi.org/10.1186/s12913-019-4545-8>
26. Tenenbaum A, Kastiel Y, Meiner Z, Kerem E. Multidisciplinary care of persons with Down syndrome in Jerusalem. *International Journal on Disability and Human Development*. 2008;7(3):355-358. <https://doi.org/10.1515/IJDHD.2008.7.3.355>
27. Lee NC, Chien YH, Hwu WL. Integrated care for Down syndrome. *Congenital Anomalies*. 2016;6(3):104-106. <https://doi.org/10.1111/cga.12159>
28. Sothirasan K, Anand AJ, Chua MPW, Khoo PC, Chua MC. Clinical guideline for management of Down syndrome in Singapore. *Proceedings of Singapore Healthcare*. 2022;31. <https://doi.org/10.1177/20101058221104582>
29. Al Farsi AJN. Attitude of pediatricians toward establishing a "Down Syndrome Clinic". *World Wide Journal of Multidisciplinary Research and Development*. 2023;9(3):16-26. Retrieved from https://wwjmr.com/upload/attitude-of-pediatricians-toward-establishing-a-down-syndrome-clinic_1678948928.pdf
30. Peters VJT, Meijboom BR, Bunt JEH, Bok LA, van Steenbergen MW, et al. Providing person-centered care for patients with complex healthcare needs: A qualitative study. *PLOS ONE*. 2020;15(11): e0242418. <https://doi.org/10.1371/journal.pone.0242418>
31. Peters VJT. Multidisciplinary care for children with Down syndrome in the Netherlands: A modular perspective. *Medical Research Archives*. 2023;11(3):1-10. <https://doi.org/10.18103/mra.v11i3.3531>
32. van den Driessen Mareeuw FA, Coppus AMW, Delnoij DMJ, de Vries E. Quality of health care according to people with Down syndrome, their parents and support staff - A qualitative exploration. *Journal of Applied Research in Intellectual Disabilities*. 2020;33:496-514. <https://doi.org/10.1111/jar.12692>
33. Haddad F, Bourke J, Wong K, Leonard H. An investigation of the determinants of quality of life in adolescents and young adults with Down syndrome. *PLoS ONE*. 2018;13(6):e0197394. <https://doi.org/10.1371/journal.pone.0197394>
34. Frankena TK, Naaldenberg J, Cardol M, Linehan C, van Schrojenstein Lantman-de Valk H. Active involvement of people with intellectual disabilities in health research - A structured literature review. *Research in Developmental Disabilities*. 2015;45-46:271-283. <https://doi.org/10.1016/j.ridd.2015.08.004>
35. Kyprianou N, Hendrix J, Hillerstrom H, Grimm R, Kirova AM, et al. Caregivers' perception of adults with Down syndrome willingness to participate in research. *Journal of Intellectual Disability Research*. 2023;67:352-361. <https://doi.org/10.1111/jir.12999>
36. Peters VJT, Bok LA, de Beer L, van Rooij JJM, Meijboom BR, et al. Destination unknown: Parents and healthcare professionals' perspectives on transition from paediatric to adult care in Down syndrome. *Journal of*

- Applied Research in Intellectual Disabilities*. 2022;35(5):1208-1216.
<https://doi.org/10.1111/jar.13015>
37. Peters VJT, de Winter JP. Integrated care for children living with complex care needs: Navigating the long and winding road. *European Journal of Pediatrics*. 2023. <https://doi.org/10.1007/s00431-023-04892-7>
38. Tobia V, Brigstocke S, Hulme C, Snowling MJ. Developmental changes in the cognitive and educational profiles of children and adolescents with 22q11.2 deletion syndrome. *Journal of Applied Research in Intellectual Disabilities*. 2018;31:e177-e181.
<https://doi.org/10.1111/jar.12344>
39. Thakur D, Martens MA, Smith DS, Roth E. Williams syndrome and music: A systematic integrative review. *Frontiers in Psychology*. 2018;9:2203.
<https://doi.org/10.3389/fpsyg.2018.02203>
40. van Eeghen AM, Stemkens D, Fernández-Fructuoso JR, Maruani A, Hadzsiev K, et al. Consensus recommendations on organization of care for individuals with Phelan-McDermid syndrome. *European Journal of Medical Genetics*. 2023;1769-7212.
<https://doi.org/10.1016/j.ejmg.2023.10474>